Dose-escalation models for combination phase I trials in oncology

Paul Hamberg; MJ Ratain; Emmanuel Lesaffre; Jaap Verweij

doi:10.1016/j.ejca.2010.07.002

Dose-escalation models for combination phase I trials in oncology

Paul Hamberg, MJ Ratain, Emmanuel Lesaffre, Jaap Verweij

Research output: Contribution to journal › Article › Academic › peer-review

40 Citations (Scopus)

Abstract

Designing combination drug phase I trials has become increasingly complex due to the increasing diversity in classes of agents mechanisms of action safety profiles and drug administration schedules With approximately 850 agents currently in development for cancer treatment it is evident that combination development must be prioritised as based on a specific hypothesis as well as a projected development path for the involved combination In this manuscript the most relevant issues and pitfalls for combination drug phase I trial design are discussed Several phase I study designs that incorporate controls to circumvent bias due to imbalances in observed background toxicity are discussed (C) 2010 Elsevier Ltd All rights reserved

Original language	Undefined/Unknown
Pages (from-to)	2870-2878
Number of pages	9
Journal	European Journal of Cancer
Volume	46
Issue number	16
DOIs	https://doi.org/10.1016/j.ejca.2010.07.002
Publication status	Published - 2010

Research programs

EMC MM-03-86-08
EMC NIHES-01-66-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2010.07.002

http://hdl.handle.net/1765/21735

Cite this

@article{765c334718e144459bb4d66ad42b8cf4,

title = "Dose-escalation models for combination phase I trials in oncology",

abstract = "Designing combination drug phase I trials has become increasingly complex due to the increasing diversity in classes of agents mechanisms of action safety profiles and drug administration schedules With approximately 850 agents currently in development for cancer treatment it is evident that combination development must be prioritised as based on a specific hypothesis as well as a projected development path for the involved combination In this manuscript the most relevant issues and pitfalls for combination drug phase I trial design are discussed Several phase I study designs that incorporate controls to circumvent bias due to imbalances in observed background toxicity are discussed (C) 2010 Elsevier Ltd All rights reserved",

author = "Paul Hamberg and MJ Ratain and Emmanuel Lesaffre and Jaap Verweij",

year = "2010",

doi = "10.1016/j.ejca.2010.07.002",

language = "Undefined/Unknown",

volume = "46",

pages = "2870--2878",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "16",

}

TY - JOUR

T1 - Dose-escalation models for combination phase I trials in oncology

AU - Hamberg, Paul

AU - Ratain, MJ

AU - Lesaffre, Emmanuel

AU - Verweij, Jaap

PY - 2010

Y1 - 2010

N2 - Designing combination drug phase I trials has become increasingly complex due to the increasing diversity in classes of agents mechanisms of action safety profiles and drug administration schedules With approximately 850 agents currently in development for cancer treatment it is evident that combination development must be prioritised as based on a specific hypothesis as well as a projected development path for the involved combination In this manuscript the most relevant issues and pitfalls for combination drug phase I trial design are discussed Several phase I study designs that incorporate controls to circumvent bias due to imbalances in observed background toxicity are discussed (C) 2010 Elsevier Ltd All rights reserved

AB - Designing combination drug phase I trials has become increasingly complex due to the increasing diversity in classes of agents mechanisms of action safety profiles and drug administration schedules With approximately 850 agents currently in development for cancer treatment it is evident that combination development must be prioritised as based on a specific hypothesis as well as a projected development path for the involved combination In this manuscript the most relevant issues and pitfalls for combination drug phase I trial design are discussed Several phase I study designs that incorporate controls to circumvent bias due to imbalances in observed background toxicity are discussed (C) 2010 Elsevier Ltd All rights reserved

U2 - 10.1016/j.ejca.2010.07.002

DO - 10.1016/j.ejca.2010.07.002

M3 - Article

C2 - 20691584

SN - 0959-8049

VL - 46

SP - 2870

EP - 2878

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 16

ER -